key: cord-1045992-mqvp28h1 authors: Yoshimi, K.; Takeshita, K.; Yamayoshi, S.; Shibumura, S.; Yamauchi, Y.; Yamamoto, M.; Yotsuyanagi, H.; Kawaoka, Y.; Mashimo, T. title: Rapid and accurate detection of novel coronavirus SARS-CoV-2 using CRISPR-Cas3 date: 2020-06-02 journal: nan DOI: 10.1101/2020.06.02.20119875 sha: 531de3812410a7c018301697ddbffd0a087c4aab doc_id: 1045992 cord_uid: mqvp28h1 Novel coronavirus SARS-CoV-2 outbreaks have rapidly spread to multiple countries, highlighting the urgent necessity for fast, sensitive, and specific diagnostic tools for virus surveillance. Here, the previously unknown collateral single-stranded DNA cleavage we observed with type I CRISPR-Cas3 highlights its potential for development as a Cas3-mediated rapid (within 40 min), low-cost, instrument-free detection method for SARS-CoV-2. This Cas3-based assay is comparable with Cas12- and real-time reverse-transcriptase PCR-based assays in its speed and sensitivity, but offers greater specificity for single-base-pair discrimination while negating the need for highly trained operators. These findings support the use of CRISPR diagnostics for point-of-care testing in patients with suspected SARS-CoV-2 infections. The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China in late December 2019, has resulted in more than 5.35 million laboratory-confirmed cases in over 210 countries, and more than 340,000 deaths as of May 25, 2020 1, 2 . The virus is mainly spread between people during close contact even before the symptoms appear 3 . During the COVID-19 outbreak on the Diamond Princess in Japan in February 2020, 3 ,700 passengers and crew members were kept aboard the ship for one month, mainly because of the capacity shortage of COVID-19 diagnostic kits 4 . Many countries use assays based on real-time (r) reverse-transcriptase (RT) polymerase chain reaction (PCR) (rRT-PCR) to detect viruses. However, the results of such assays on clinical samples from people with suspected SARS-CoV-2 infections are generally not ready until the day after sample collection because the samples need be shipped to reference laboratories for accurate diagnostic testing 5, 6 . rRT-PCR assays also require expensive equipment and well-trained personnel for their operation, making them unsuitable for point-of-care test (POCT) applications, but a POCT would have benefited the situation on the ship. Enzymes from CRISPR-Cas systems have recently been adapted to rapidly, robustly, and sensitively detect viruses. These systems rely on Cas12a, otherwise called DETECTR (DNA Endonuclease-TargEted CRISPR Trans Reporter) 7 , and Cas13, otherwise called SHERLOCK (Specific High-sensitive Enzymatic Reporter UnLOCKing) 8 . Both of these Cas enzymes, but not Cas9, exhibit nonspecific endonuclease activity in trans after binding to a specific cis target via programmable CRISPR RNAs (crRNAs). By combining isothermal amplification methods (e.g., Recombinase Polymerase Amplification, RPA 9 ; or Loop-mediated isothermal . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint AMPlification, LAMP 10 ) with reporting formats such as lateral flow detection with antigen-labeled reporters 11, 12 , DETECTR [12] [13] [14] and SHERLOCK 15, 16 have recently been used for rapid and highly sensitive SARS-CoV-2 detection. The Cas13-based strategy, PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells), has also been shown to inhibit and degrade SARS-CoV-2 viral RNA in respiratory epithelial cells 17 . We and other groups have recently reported that Class 1 Type I-E CRISPR-Cas from Escherichia coli 18 and Thermobifida fusca 19 First, to investigate whether Class 1 CRISPR-Cas3 exhibits trans-cleavage activity on collateral ssDNA, we assembled the E. Coli Cas3 protein (20 ng/µL), Cascade with its crRNA (32 ng/µL), the double-stranded DNA (dsDNA) activator (2 ng/µL) for two target genes, human EMX1 or mouse Tyr (Table S1 and S2), and a fluorophore quencher (FQ)-labeled ssDNA probe (4.5 ng/µL) in the reaction buffer (5 mM HEPES-K pH7.5, 60 mM KCl, 10 mM MgCl 2 , 10 μM CoCl 2 , and 2.5 mM ATP). After 10 min incubation at 37ºC, we observed non-specific trans-ssDNA cleavage after . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint site-specific dsDNA cutting within the positive (+) strand, but not the negative (-) strand ( Figure 1b ). We screened all 64 possible target sites containing each of the three-nucleotide protospacer adjacent motif (PAM) sequences (Figure 1c and Fig. S1a ), and observed significant cleavage activities with 14 PAM types. The highest activity was from AAG, whereas no activity was seen with the first and the second C nucleotides and the third T nucleotide in the PAM. Therefore, we called this protocol Cas3-Operated Nucleic Acid Detection, or CONAN ( Figure 1a ). We then investigated the detection sensitivity of CONAN by diluting the hEMX1 or mTyr dsDNA activator with Cas3, Cascade and FQ-ssDNA in the reaction buffer. CONAN's limit of detection (LoD) was >1.0 x 10 10 copies for the activator (Fig. S1b ). To improve the LoD, we performed isothermal RPA at 37ºC for 30 min, followed by a 10 min incubation with Cascade and Cas3, thereby determining the activator's single-copy sensitivity level (Figure 1d ). We also achieved robust detection of the single-copy activator after mixing it with abundant mouse genomic DNA (Figure 1e ). Detecting FQ-ssDNA cleavage needs a microplate reader for fluorescence intensity measurement. Instead of this laboratory instrument, a lateral flow strip can be used for instrument-free and portable diagnosis by the virus POCT 11, 12 . In principle, abundant reporter accumulates anti-FITC antibody-gold nanoparticle conjugates at the first line (negative) on the strip, while cleavage of the reporter would reduce accumulation on the first line and result in signal on the second line (positive) with <2 min of flow (Fig. S2 ). Using this lateral flow strip we achieved a one-pot assay with CONAN-RPA, thereby detecting a single copy level of the target dsDNA within 40 min. We next examined whether the CONAN lateral flow assay would be effective for SARS-CoV-2 diagnosis (Figure 2a ), as has been recently reported for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint DETECTR 12-14 and for SHERLOCK 15, 16 . We designed primers to amplify the N (nucleoprotein) gene regions (N1 and N2) from SARS-CoV-2 (Table S3) , which overlap with the region used in the DTECTER-based assay 13 , along with primers for the qRT-PCR assay from the US CDC 22 . The qRT-PCR assay successfully amplified both the N1 and N2 regions of SARS-CoV-2, with LoDs of <10 2 copies (Figure 2b) . We compared the CONAN-and DETECTR-based assays by designing crRNAs in the N1 and N2 regions (Table S1 ). However, RT-RPA followed by Cas3-based CONAN or Cas12-based DETECTOR in the one-step 37ºC 1-h incubation did not effectively detect SARS-CoV-2, probably because the N1 and N2 primers we designed did not match the sensitivity of the RT-based assay (Fig. S3a ). Designing primers for LAMP assays can be complicated, but the upside is that these assays seem to be less sensitive to inhibitors or off-target nucleic acid contamination in the samples. RT-LAMP at 62ºC for 30 min, followed by CONAN or is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint agreement; 90% and negative predictive agreement; 95%). One negative swabs from COVID-19 patients was confirmed to be below the established LoD of <10 2 copies (Fig. S3b ). This 94% detection rate (29/31) is comparable with that of the DETECTR RT-LAMP assay in this study ( Figure 2e ) and that previously reported for a COVID-19 CRISPR-based diagnostic (CRISPR-dx) nucleic acid tests have been used to detect the presence DNA or RNA in a range of samples across biotechnology and health areas 7, 8, 24, 25 . They mainly include type V Cas12a DETECTR [12] [13] [14] and Cas13 type VI SHERLOCK 15, 16 , which both belong to Class II CRISPR. Here, we report on the discovery of Class I Cas3-mediated collateral trans cleavage activity. Our newly developed a CONAN lateral flow assay, which uses this type of collateral cleavage, facilitated the rapid, robust, and sensitive detection of novel coronavirus SARS-CoV-2. Unlike the single Cas12a and Cas13 platforms, CONAN needs multiple Cas proteins (Cas3, 5, 6, 7, 8, and 11), but they are stable when premixed and stored at around 4ºC. Interestingly, unlike DETECTR, CONAN shows high specificity for single-base-pair discrimination within the PAM site ( is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint for implementation. In contrast, serology IgM/IgG tests with lateral flow immunoassays can rapidly and sensitively determine the infection rate in a population, although IgG antibodies to SARS-CoV-2 are generally only detectable 10-14 days post-infection. SARS-CoV-2 antigen tests can directly detect viral components without the amplification steps needed for RT-PCR and LAMP; however, the technology is new and the evidence for its accuracy in coronavirus diagnosis is still being evaluated. CRISPR-dx is also cheaper and allows portable diagnostic tests for the assessment of suspected cases without the need for sophisticated equipment. Although still awaiting evaluation, CRISPR-dx methods have high potential for transforming pathogen identification and other aspects of infectious disease diagnostics, such as that relating to SARS-CoV-2. CRISPR-Cas3 and CRISPR-Cas12a target sites were based on the human EMX1 gene, the mouse Tyr gene, and the N gene from SARS-CoV-2 (Supplementary Table 1 Cascade-crRNA was also purified using Ni-NTA resin and size-exclusion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint chromatography in 350 mM NaCl, 1mM DTT and 20 mM HEPES-Na (pH 7.0). AsCas12a and LbCas12a were purchased from Integrated DNA Technologies (IDT, Coralville, IA) and New England Biolabs (NEB, Ipswich, Massachusetts), respectively. Target-specific crRNAs were also purchased from IDT. For the CRISPR-Cas3 activator templates, 60 bp fragments of hEMX1 and mTyr (which included a target site) were designed and purchased from IDT. PAM variants in hEMX1 were also designed to examine the correlation between collateral cleavage activity and PAM specificity (Supplementary Table 2 Real-time rRT-PCR was used to determine SARS-CoV-2 RNA copy numbers using . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint as described in the NIID-approved protocol (input 140 µl; elution, 60 µl) using the Viral RNA Mini kit (QIAGEN). The data that support the findings of this study are available from the corresponding authors upon reasonable request. Pathogenesis (CRIP; HHSN272201400008C). We thank Sandra Cheesman, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. K.Y. designed and performed most of the experiments and analyzed the data with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint rRT-PCR assay). PPA: positive predictive agreement. NPA: negative predictive agreement. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. TGGCGCATTGCCACGCTGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-CTT-60bp TGGCGCATTGCCACGCTTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GAA-60bp TGGCGCATTGCCACGGAACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GAC-60bp TGGCGCATTGCCACGGACCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GAG-60bp TGGCGCATTGCCACGGAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GAT-60bp TGGCGCATTGCCACGGATCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GCA-60bp TGGCGCATTGCCACGGCACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GCC-60bp TGGCGCATTGCCACGGCCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GCG-60bp TGGCGCATTGCCACGGCGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GCT-60bp TGGCGCATTGCCACGGCTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GGA-60bp TGGCGCATTGCCACGGGACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GGC-60bp TGGCGCATTGCCACGGGCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GGG-60bp TGGCGCATTGCCACGGGGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GGT-60bp TGGCGCATTGCCACGGGTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GTA-60bp TGGCGCATTGCCACGGTACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GTC-60bp TGGCGCATTGCCACGGTCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GTG-60bp TGGCGCATTGCCACGGTGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-GTT-60bp TGGCGCATTGCCACGGTTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TAA-60bp TGGCGCATTGCCACGTAACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TAC-60bp TGGCGCATTGCCACGTACCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TAG-60bp TGGCGCATTGCCACGTAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TAT-60bp TGGCGCATTGCCACGTATCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TCA-60bp TGGCGCATTGCCACGTCACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TCC-60bp TGGCGCATTGCCACGTCCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TCG-60bp TGGCGCATTGCCACGTCGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TCT-60bp TGGCGCATTGCCACGTCTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TGA-60bp TGGCGCATTGCCACGTGACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TGC-60bp TGGCGCATTGCCACGTGCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TGG-60bp TGGCGCATTGCCACGTGGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TGT-60bp TGGCGCATTGCCACGTGTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TTA-60bp TGGCGCATTGCCACGTTACAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TTC-60bp TGGCGCATTGCCACGTTCCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TTG-60bp TGGCGCATTGCCACGTTGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG EMX1-TTT-60bp TGGCGCATTGCCACGTTTCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAG mTyr-AAG-60bp GCATTACTATGTGTCAAGGGACACACTGCTTGGGGGCTCTGAAATATGGAGGGACATTGA . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint Sequence ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2020. . https://doi.org/10.1101/2020.06.02.20119875 doi: medRxiv preprint A Novel Coronavirus from Patients with Pneumonia in China A novel coronavirus outbreak of global health concern Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Coronavirus and the race to distribute reliable diagnostics CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity Nucleic acid detection with CRISPR-Cas13a/C2c2 SHERLOCK: nucleic acid detection with CRISPR nucleases An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12. bioRxiv CRISPR-Cas12-based detection of SARS-CoV-2 All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus. bioRxiv Massively multiplexed nucleic acid detection using Cas13 CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design. bioRxiv Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza 60bp CAGCACTCTGCCCTCGTGGGAGTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-ATAG-60bp CAGCACTCTGCCCTCGTGGGATAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-ATCG-60bp CAGCACTCTGCCCTCGTGGGATCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-ATGG-60bp CAGCACTCTGCCCTCGTGGGATGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-ATTG-60bp CAGCACTCTGCCCTCGTGGGATTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CAAG-60bp CAGCACTCTGCCCTCGTGGGCAAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CACG-60bp CAGCACTCTGCCCTCGTGGGCACGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CAGG-60bp CAGCACTCTGCCCTCGTGGGCAGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CATG-60bp CAGCACTCTGCCCTCGTGGGCATGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CCAG-60bp CAGCACTCTGCCCTCGTGGGCCAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CCCG-60bp CAGCACTCTGCCCTCGTGGGCCCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CCGG-60bp CAGCACTCTGCCCTCGTGGGCCGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CCTG-60bp CAGCACTCTGCCCTCGTGGGCCTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CGAG-60bp CAGCACTCTGCCCTCGTGGGCGAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CGCG-60bp CAGCACTCTGCCCTCGTGGGCGCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CGGG-60bp CAGCACTCTGCCCTCGTGGGCGGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CGTG-60bp CAGCACTCTGCCCTCGTGGGCGTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CTAG-60bp CAGCACTCTGCCCTCGTGGGCTAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CTCG-60bp CAGCACTCTGCCCTCGTGGGCTCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CTGG-60bp CAGCACTCTGCCCTCGTGGGCTGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-CTTG-60bp CAGCACTCTGCCCTCGTGGGCTTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GAAG-60bp CAGCACTCTGCCCTCGTGGGGAAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GACG-60bp CAGCACTCTGCCCTCGTGGGGACGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GAGG-60bp CAGCACTCTGCCCTCGTGGGGAGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GATG-60bp CAGCACTCTGCCCTCGTGGGGATGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GCAG-60bp CAGCACTCTGCCCTCGTGGGGCAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GCCG-60bp CAGCACTCTGCCCTCGTGGGGCCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GCGG-60bp CAGCACTCTGCCCTCGTGGGGCGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GCTG-60bp CAGCACTCTGCCCTCGTGGGGCTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GGAG-60bp CAGCACTCTGCCCTCGTGGGGGAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GGCG-60bp CAGCACTCTGCCCTCGTGGGGGCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GGGG-60bp CAGCACTCTGCCCTCGTGGGGGGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GGTG-60bp CAGCACTCTGCCCTCGTGGGGGTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GTAG-60bp CAGCACTCTGCCCTCGTGGGGTAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GTCG-60bp CAGCACTCTGCCCTCGTGGGGTCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GTGG-60bp CAGCACTCTGCCCTCGTGGGGTGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-GTTG-60bp CAGCACTCTGCCCTCGTGGGGTTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TAAG-60bp CAGCACTCTGCCCTCGTGGGTAAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TACG-60bp CAGCACTCTGCCCTCGTGGGTACGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TAGG-60bp CAGCACTCTGCCCTCGTGGGTAGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TATG-60bp CAGCACTCTGCCCTCGTGGGTATGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TCAG-60bp CAGCACTCTGCCCTCGTGGGTCAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TCCG-60bp CAGCACTCTGCCCTCGTGGGTCCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TCGG-60bp CAGCACTCTGCCCTCGTGGGTCGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TCTG-60bp CAGCACTCTGCCCTCGTGGGTCTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TGAG-60bp CAGCACTCTGCCCTCGTGGGTGAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TGCG-60bp CAGCACTCTGCCCTCGTGGGTGCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TGGG-60bp CAGCACTCTGCCCTCGTGGGTGGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TGTG-60bp CAGCACTCTGCCCTCGTGGGTGTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TTAG-60bp CAGCACTCTGCCCTCGTGGGTTAGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TTCG-60bp CAGCACTCTGCCCTCGTGGGTTCGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TTGG-60bp CAGCACTCTGCCCTCGTGGGTTGGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT EMX1-TTTG-60bp CAGCACTCTGCCCTCGTGGGTTTGTGGTTGCCCACCCTAGTCATTGGAGGTGACATCGAT